Aripiprazole for Nausea and Vomiting
Aripiprazole is not recommended as a standard antiemetic agent for nausea and vomiting, as it lacks evidence from clinical guidelines and controlled trials, and nausea/vomiting are actually listed as common adverse effects of the drug itself.
Evidence Against Use
FDA-Labeled Adverse Effects
- Nausea and vomiting are documented as common side effects of aripiprazole in adults, occurring frequently enough to be listed in the FDA prescribing information 1.
- In pooled clinical trial data, nausea occurred in a significant proportion of patients taking aripiprazole, making it an unlikely candidate for antiemetic therapy 1.
- Vomiting is specifically listed among the most common adverse reactions in both adult and pediatric populations receiving aripiprazole 1.
Absence from Clinical Guidelines
- Major antiemetic guidelines from the American Gastroenterological Association (2022) do not include aripiprazole in their comprehensive treatment tables for refractory gastroparesis, despite listing numerous dopamine antagonists and other antipsychotics 2.
- The National Comprehensive Cancer Network (NCCN) antiemetic guidelines (2017) recommend haloperidol and chlorpromazine as antipsychotic options for breakthrough chemotherapy-induced nausea/vomiting, but do not mention aripiprazole 3.
- American Society of Clinical Oncology (ASCO) guidelines (2017) recommend olanzapine for breakthrough nausea but make no reference to aripiprazole 4.
Limited Preclinical Evidence
Single Animal Study
- One 2007 preclinical study in ferrets showed that aripiprazole reduced morphine-induced emesis, similar to haloperidol, through dopamine system stabilization 5.
- However, this finding has never been validated in human clinical trials and remains purely experimental 5.
Preferred Alternatives with Strong Evidence
First-Line Antiemetics
- 5-HT₃ receptor antagonists (ondansetron 4-8 mg twice or three times daily, granisetron 1 mg twice daily) have established efficacy for nausea and vomiting across multiple conditions 2, 6.
- Dopamine D₂ antagonists with proven efficacy include prochlorperazine (5-10 mg four times daily), chlorpromazine (10-25 mg three to four times daily), and metoclopramide (5-20 mg three to four times daily) 2, 3.
Atypical Antipsychotic with Evidence
- Olanzapine (5-10 mg daily) is the only atypical antipsychotic with Category 1 evidence for breakthrough chemotherapy-induced nausea/vomiting, demonstrating superiority over metoclopramide in controlled trials 4, 3.
Clinical Pitfalls
- Do not confuse aripiprazole's dopamine "system-stabilizing" properties with antiemetic efficacy—its partial agonist activity at D₂ receptors differs mechanistically from the full antagonism required for antiemetic effect 5, 7.
- Aripiprazole may paradoxically worsen nausea given its adverse effect profile, particularly during treatment initiation 1.
- If an atypical antipsychotic is needed for refractory nausea, olanzapine has the strongest evidence base and should be selected instead 4, 3.